STK11 and metastatic neoplasm: The majority (71% (29/41)) of the 41 metastatic tumors showing LKB1 loss were non-pleomorphic LUACs, while 9.8% (4/41) were pleomorphic LUACs, and 15% (6/41) were LSCCs [Supplementary Table S13].